Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novo Nordisk Enjoys Obesity Sales Boost Despite Wegovy Supply Issues

Reports 82% Growth In Q3

Nov 04 2021

• By Ayisha Sharma

Related Content

Keeping Track: US FDA Approves Novartis’ Scemblix; Lilly Submits Tirzepatide, Withdraws Tanezumab

Oct 30 2021

Novo’s H1 Exceeds Estimates On GLP-1, Obesity Sales Performance

Aug 05 2021

Related Companies

Novo Nordisk A/S

Eli Lilly and Company

Boehringer Ingelheim GmbH

AstraZeneca PLC

Additional Topics

Sales & Earnings Companies Commercial Metabolic Disorders BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.